Transcept Pharmaceuticals Issues Update On Intermezzo Regulatory Review
Transcept Pharmaceuticals submitted a revised proposal for the resubmission of the Intermezzo New Drug Application (NDA) to the FDA for evaluation and comment. The FDA stated in the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.